.svg){kind=icon}
Explore More
- 2025 Indicators of Progress for Advancing Health Globally
- 2025 Indicators of Progress for the Life Sciences Sector
- Achieving CAR T-cell Therapy Health System Readiness
- Advancing Equitable and Timely Access to Personalized Oncology Therapies: Middle East and Africa
- Advancing Evidence-Based Academic Research 2025
- Advancing Precision Oncology
- America's Greatness in the Biopharmaceutical Sector
- Assessing Availability of New Drugs in Europe, Japan, and the U.S.
- Quantifying Differences in Female and Male Healthcare
- Assessing the Biosimilar Void in the U.S.
- Assessing the Impact of State Pharmacist Vaccination Authority on Vaccine Uptake in the U.S.
- Biosimilar Sustainability Scorecards for Europe 2026
- Developing Efficient Patient Referral Pathways for Radioligand Therapies
- Digital Health Trends 2024
- Digital Health Trends 2025
- Drug Expenditure Dynamics 2000–2022
- Expanding Options for Emerging Biopharma in the U.S.: A Decade of Change
- Global Medicine Use Trends 2026
- Global Oncology Trends 2025
- Global R&D Trends 2026
- HIV Spending Trends
- Impacts of the Proliferation of Innovation
- Key Access Pathways and Bottlenecks for Medicines in LMICs: Data Insights into Recently Launched and Established Medicines
- Measuring the Estimated Size of the U.S. Pharmaceutical Market on a Net Manufacturer Price Basis
- Modeling Policy Proposals for Medical Benefit Biosimilar Reimbursement in the U.S.
- Oncology Therapy Access in the Era of Personalized Medicine
- Optimizing Care Delivery for Patients With Cancer
- Proliferation of Innovation Over Time
- Trends in Drug Shortages and ANDA Approvals in the U.S.
- Unlocking Biosimilar Potential
- Unlocking Biosimilar Potential
- U.S. Medicine Use Trends 2026
- 15+ Years of Biosimilar Experience in Europe
- Accelerating Health Equity: Challenges and Opportunities
- Advancing Academic Research 2022
- Advancing Evidence-Based Academic Research 2024
- Advancing Diversity in Clinical Development through Cross-Stakeholder Commitment and Action
- Assessing the Biosimilar Void
- Assessing the Impact of Illegal Online Pharmacies in the U.S.
- Biosimilars in the United States 2023-2027
- Defining Essential Innovative Medicines and Measuring their Use in Europe
- Drug Shortages in the U.S. 2023
- Emerging Biopharma’s Contribution to Innovation
- Hematologic Cancer Opportunities for Patient Equality (HOPE)
- Hematologic Cancer Opportunities for Patient Equality (HOPE)
- Human Data Science Research Collaborative
- Impact of RWE on HTA Decision-making
- Improving Decision-Making through Connected Intelligence
- Inflation Reduction Act Implementation
- Key Context for CMS Prescription Drug Negotiations
- Lesson Learned from COVID-19 Vaccine Trials
- Long-term Market Sustainability for Infused Biosimilars in the U.S.
- Medical Dermatology
- Pathway to Success in Cancer Treatment
- Patient Organization Research Collaborations: Interactions with Life Sciences Companies
- Policy Proposals to Achieve Long-term Sustainability of Infused Biosimilars in the U.S.
- Protection Expiry and Journey into the Market
- Rethinking Clinical Trial Country Prioritization
- Rethinking Obesity
- Scaling-up Inclusive Healthcare in Low- and Middle-Income Countries 2
- Scaling-Up Inclusive Healthcare Initiatives in Low- and Middle-Income Countries
- Shared Savings Programs in Europe
- Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios
- Succeeding with Innovation: The State of Radioligand Therapy Readiness in Europe
- Supporting patients through research collaboration
- Trends in Adult Vaccination in the U.S.
- Trends in Global Adult Vaccination
- Trends in Global Adult Vaccination: A View from Five Global Cities
- Trends in Vaccine Administration in the United States
- Unlocking Biosimilar Potential
- U.S.-India Medicine Partnership: India's Contribution to the U.S. Healthcare System
- Advancing Academic Research 2021
- Advancing Academic Research Bibliography 2020
- Advancing Pediatric Cancer Research
- Assessing the Global Burden of Post-COVID-19 Conditions
- Biosimilars in the United States 2020–2024
- Cancer Wont Wait
- Country Scorecards for Biosimilar Sustainability
- Diabetes Costs and Affordability in the United States
- Digital Health Trends 2021
- Drug Expenditure Dynamics 1995–2020: Understanding medicine spending in context
- Drug Expenditure Dynamics 1995-2021: Understanding Medicine Spending in Context - Country Detail Appendices
- Evolving Oncology Endpoints
- Improving Patient Adherence and Health Outcomes
- Innovation in Diabetes Care Technology: Barriers to Reimbursement
- Innovation in Diabetes Care Technology: The User Experience
- Innovation in Diabetes Care Technology: Value-based Agreements
- Innovative Funding for Medicines in Latin America
- Lung Cancer Won't Wait
- Operating Margin Dynamics for Life Sciences Companies
- Optimizing Healthcare Sustainability in Japan
- Optimizing Insulin Use Through Smart Pens: Challenges and Opportunities in Europe
- Optimizing Oncology Care Through Biomarker Adoption
- Orphan Drugs in the United States Rare disease innovation and cost trends through 2019
- Prescription Opioid Trends in the United States
- Reopening the US Health System
- Expectations about Seismic Shifts in Global Healthcare Spending and Payment Reforms
- The Impact of Pharmaceutical IP Provisions in EU Free Trade Agreements
- The New Decade of Health and Science
- The Prospects for Biosimilars of Orphan Drugs in Europe
- Understanding Insulin Market Dynamics in Low and Middle Income Countries
- Understanding Medicine Spending in Australia
- Understanding the Global Landscape of Genomic Initiatives
- Valuing the Research based Pharmaceutical Industry in Latin America
- Reports Archive
LAAD HIER MEER